News | November 18, 2011

First Patients Implanted with Watchman LAA Occluder in Latin America

November 18, 2011 – Boston Scientific’s Watchman left atrial appendage (LAA) closure device has been implanted in the first patients in Latin America. The device is designed for use in patients in atrial fibrillation who are at risk for stroke and are eligible for long-term oral anticoagulation therapy such as warfarin. Watchman is intended to prevent embolization of thrombi that may form in the LAA, thereby preventing the occurrence of ischemic stroke and systemic thromboembolism in patients with non-valvular atrial fibrillation. The first patient implants were performed by Bernardo Caicedo, M.D., interventional cardiologist, at Angiografia de Occidente in Cali, Colombia.

Atrial fibrillation, which affects approximately 15 million patients worldwide, is a disorder that disrupts the heart's ability to beat regularly and pump blood efficiently. Patients in atrial fibrillation are at greater risk for stroke due to the formation and migration of clots in the left atrial appendage. Anticoagulants such as warfarin have traditionally been the only therapy for reducing stroke risk in these patients. Watchman is intended to be an alternative to long-term anticoagulation. It is designed to close the LAA, thereby preventing clots within the appendage from being dislodged into the bloodstream.

"I am excited to be part of the first patient implants of the Watchman device in Latin America," said Caicedo. "The percutaneously delivered device promises to offer a safe and effective alternative for atrial fibrillation patients who cannot take long-term oral anticoagulants and have limited options to reduce their stroke risk. It incorporates a pre-loaded device that is both repositionable and retrievable to enhance its ease of use."

Watchman is the most clinically studied product of its kind currently available. In the multi-center, randomized PROTECT AF clinical trial, it proved to be non-inferior to warfarin and demonstrated a 38 percent relative risk reduction for a combined measure of stroke, cardiovascular death and systemic embolism compared to long-term warfarin therapy in 800 patients. The study also showed a 29 percent relative risk reduction in all stroke and a 90 percent relative risk reduction in hemorrhagic stroke compared to warfarin. Nearly 1,800 patients have now been recruited in Wacthman clinical trials with more than 2,700 patient-years of follow-up. Watchman is CE Marked and was commercialized outside the United States in 2009.

Boston Scientific is currently enrolling United States patients in the PREVAIL study, a confirmatory study designed to gain U.S. Food and Drug Administration (FDA) approval. Enrollment is expected to be completed in the first quarter of 2012. In the United States, Watchman is an investigational device, limited by applicable law to investigational use and not available for sale. The device was developed by Atritech, which Boston Scientific acquired in March 2011.

For more information: www.bostonscientific.com

 

Related Content

News | Cardiac Diagnostics| September 12, 2017
Contracting shingles, a reactivation of the chickenpox virus, increases a person’s risk of stroke and heart attack,...
LAA closure during open heart surgery in the LAACS Study showed better outcomes for all patients.

LAA closure during open heart surgery in the LAACS Study showed better outcomes for all patients.

Feature | Left Atrial Appendage (LAA) Occluders| September 07, 2017
September 7, 2017 — Closure of the left atrial appendage (LAA) during heart surgery protects the brain, according to
Protembis Announces Successful First-in-Human Use of  ProtEmbo Cerebral Protection System in European Trial
News | Embolic Protection Devices| September 07, 2017
Protembis GmbH announced the first clinical applications of its ProtEmbo Cerebral Protection System to complement a...
PinnacleHealth First in Pennsylvania to Implant Sentinel Cerebral Protection System
News | Embolic Protection Devices| August 23, 2017
PinnacleHealth is the first hospital in Pennsylvania and one of the first 10 in the country to introduce new technology...
SanBio Receives $20 Million Grant for Stroke Clinical Trial
News | Stroke| July 12, 2017
July 12, 2017 — SanBio Inc.
German Workshop Highlights Possibilities of Perfusion MRI
News | Stroke| July 03, 2017
When diagnosing strokes and heart diseases or looking at tumors, perfusion magnetic resonance imaging (MRI) offers a...
Stroke History Higher in Asymptomatic Versus Symptomatic Atrial Fibrillation Patients
News | Stroke| June 28, 2017
Newly diagnosed asymptomatic atrial fibrillation patients have a higher rate of previous stroke than those with...
Analysis Shows Increased Risk of Early Stroke with New-Onset Atrial Fibrillation Post-TAVR, SCAI 2017 late-breaking clinical trial
News | Stroke| May 12, 2017
More than one-third of patients undergoing transcatheter aortic valve replacement (TAVR) were observed to have atrial...
AtriCure's AtriClip System Surpasses 100,000 Units Sold Worldwide
News | Left Atrial Appendage (LAA) Occluders| April 25, 2017
AtriCure Inc. announced it has sold more than 100,000 AtriClip Left Atrial Appendage Exclusion System devices worldwide...
3-D-printed Model of Stenotic Intracranial Artery Enables Vessel-Wall MRI Standardization
News | 3-D Printing| April 18, 2017
A collaboration between stroke neurologists at the Medical University of South Carolina (MUSC) and bioengineers at the...
Overlay Init